In March 2025, SFA Therapeutics announced that two head-to-head preclinical studies of its oral psoriasis therapy candidate, ...

Codex Labs has announced the launch of the first product in a new collection, KĀNGFÙ, that is focused on healing damaged skin ...

The skin on different areas of the body requires different regimens. Here’s how dermatologists recommend treating it on your ...

Topicals are often the first-line treatment for psoriasis, but as the condition progresses, you may need to consider systemic treatments to manage your symptoms. Here’s what to know about your options ...

Sustainability is a very important topic in our work, outside of the scientific part of the Congress. It was started as a ...

First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company's XTR ...

The use of dupilumab for the treatment of atopic dermatitis was associated with an increased risk of psoriasis compared with other systemic agents. The association between dupilumab and psoriasis was ...

The recent FDA approval of topical JAK inhibitors for children 2 years or older marks a significant advancement in pediatric ...

Yuflyma is a TNF blocker approved as a citrate-free, high-concentration, interchangeable biosimilar to Humira (adalimumab).

YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV), in the ...